Relacatib

• CAT Number: I008995
• CAS Number: 362505-84-8
• Molecular Formula: C27H32N4O6S
• Molecular Weight: 540.635
• Purity: ≥95%
• Synonyms: SB462795; SB-462795; SB 462795; GSK462795; GSK-462795; GSK 462795; D06634;N-((S)-4-methyl-1-(((4S,7R)-7-methyl-3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-yl)amino)-1-oxopentan-2-yl)benzofuran-2-carboxamide.
• Target: Cathepsin
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: N-[(2S)-4-methyl-1-[[(4S,7R)-7-methyl-3-oxo-1-pyridin-2-ylsulfonylazepan-4-yl]amino]-1-oxopentan-2-yl]-1-benzofuran-2-carboxamide
• InChI: InChI=1S/C27H32N4O6S/c1-17(2)14-21(30-27(34)24-15-19-8-4-5-9-23(19)37-24)26(33)29-20-12-11-18(3)31(16-22(20)32)38(35,36)25-10-6-7-13-28-25/h4-10,13,15,17-18,20-21H,11-12,14,16H2,1-3H3,(H,29,33)(H,30,34)/t18-,20+,21+/m1/s1
• InChIKey: BWYBBMQLUKXECQ-GIVPXCGWSA-N
• SMILES: CC1CCC(C(=O)CN1S(=O)(=O)C2=CC=CC=N2)NC(=O)C(CC(C)C)NC(=O)C3=CC4=CC=CC=C4O3

Relacatib is a potent and selective inhibitor of cathepsin K, an enzyme involved in the degradation of collagen and other proteins in bone tissue. It has been investigated as a potential therapeutic agent for the treatment of osteoporosis and other bone-related disorders, where excessive bone resorption occurs. By inhibiting cathepsin K, Relacatib helps reduce bone loss and maintain bone density. Although promising in early studies, its development has been closely monitored for efficacy and safety in long-term use.